Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of LY3526318 in Healthy Male Japanese Participants
- Conditions
- Interventions
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2023-01-09
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT05580250
- Locations
- 🇯🇵
Souseikai Fukuoka Mirai Hospital, Fukuoka, Japan
A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy Participants
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2023-02-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 32
- Registration Number
- NCT05573230
- Locations
- 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore
A Study of Donanemab (LY3002813) in Healthy Participants
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 42
- Registration Number
- NCT05567159
- Locations
- 🇺🇸
ICON Early Phase Services Lenexa Center, Salt Lake City, Utah, United States
A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]
- Conditions
- Interventions
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 216
- Registration Number
- NCT05565742
- Locations
- 🇩🇪
Diabeteszentrum Hamburg West, Hamburg, Germany
🇷🇴Cardiomed Iași, Iași, Romania
🇦🇷Glenny Corp. S.A., Buenos Aires, Ciudad Aut, Argentina
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 282
- Registration Number
- NCT05564039
- Locations
- 🇺🇸
Juno Research, Houston, Texas, United States
🇺🇸Biopharma Informatic, LLC, Houston, Texas, United States
🇷🇴Diabdana, Oradea, Bihor, Romania
A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 233
- Registration Number
- NCT05563246
- Locations
- 🇺🇸
Care Access - Baltimore, Baltimore, Maryland, United States
🇦🇺Nightingale Research, Adelaide, South Australia, Australia
🇺🇸Care Access - Dorchester, Dorchester, Massachusetts, United States
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2022-09-29
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 360
- Registration Number
- NCT05559359
- Locations
- 🇺🇸
Great Lakes Research Group, Inc., Bay City, Michigan, United States
🇯🇵Asahikawa Medical College Hospital, Asahikawa, Hokkaido, Japan
🇺🇸Antelope Valley Clinical Trials, Lancaster, California, United States
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 15374
- Registration Number
- NCT05556512
- Locations
- 🇦🇹
Universitaetsklinikum Allgemeines Krankenhaus Wien, Vienna, Wien, Austria
🇧🇷CEPIC - Centro Paulista de Investigação Clínica, São Paulo, Brazil
🇲🇽Caimed Investigacion En Salud S.A. de C.V., Mexico City, Distrito Federal, Mexico
A Study of LY3437943 in Chinese Participants With Obesity Or Overweight
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 32
- Registration Number
- NCT05548231
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Cheng Du, Sichuan, China
🇨🇳Peking University First Hospital, Beijing, China
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2022-09-13
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 140
- Registration Number
- NCT05536804
- Locations
- 🇺🇸
American Health Network of Indiana, LLC - Avon, Avon, Indiana, United States
🇨🇦Centre intégré universitaire de santé et de services sociaux de l'Estrie Centre Hospitalier Universitaire -T, Sherbrooke, Quebec, Canada
🇺🇸Valley Clinical Trials, Inc., Northridge, California, United States